Free Daily Podcast Summary
Beyond Biotech - the podcast from Labiotech: Daily Summaries Delivered
by Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 4 days ago40 min
The best biotech conversations you missed this summer
Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months. We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of ...
- 1 weeks ago30 min
Rewriting the rules of genetic medicine with tRNA therapeutics
Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic...
- 2 weeks ago31 min
How Evox Therapeutics is targeting CNS diseases with exosomes
Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whether gene editing can do the same. My guest today is Dr. Per Lundin, Co-Founder and CEO of Evox Therape...
- 3 weeks ago34 min
BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech
Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country, the event runs from 29 September to 1 October at the Bilbao Exhibition Centre. In this episode w...
- Aug 21, 202631 min
Beyond biology: Nanobiotix's physics-first approach to cancer
What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic. Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and ...
- Aug 14, 202643 min
How Cancer Research Horizons is building the future of childhood cancer medicines
Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides. Tony Hickson is Chief Business Officer for Cancer Research Horizons, Cancer Research UK's innovation engine, respon...
- Aug 7, 202636 min
Why Western pharma is sleeping on China's circular RNA revolution
RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of ...
- Jul 31, 202642 min
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the CEO role in early 2025. Gain Therapeutics is a clinical-stage biotech pioneering next-generation allosteric small molecule therapies. Using its proprietary Magellan platform, which combines 3D struc...
About Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Beyond Biotech - the podcast from Labiotech in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Beyond Biotech - the podcast from Labiotech daily summary?
It's a free AI-powered email that summarizes new episodes of Beyond Biotech - the podcast from Labiotech as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Beyond Biotech - the podcast from Labiotech podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Beyond Biotech - the podcast from Labiotech product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Labiotech.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Beyond Biotech - the podcast from Labiotech release new episodes?
Beyond Biotech - the podcast from Labiotech publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does Beyond Biotech - the podcast from Labiotech cover?
Beyond Biotech - the podcast from Labiotech covers topics including News. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Beyond Biotech - the podcast from Labiotech summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.